This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Summary statistics from each study.
Number of primary studies included
Approximately 7 studies were included in the review.
Methods of combining primary studies
Narrative method.
Investigation of differences between primary studies
Results of the review
9% of patients died from all causes during treatment. 3.5% of patients who completed therapy relapsed. 75% of relapses occurred within a year, another 20% within the second year, and the remaining 5% spread equally across years 3 to 10. Each patient with active TB had 9.8 contacts, 92% of these contacts were examined for TB and 0.7% of those examined had active TB. 22% of those examined had TB infection and 16% of all contacts were placed on preventive therapy. Preventive therapy effectiveness was estimated to be 65% for MDR TB-infected and non-MDR TB-infected patients. For newly infected contacts, the risk of developing active TB was 4% in the first year following infection, and 1% per year for the following four years. 35% of patients were hospitalised for diagnosis of TB prior to outpatient treatment. Patients with drug-susceptible TB had a mean hospital stay of 20 days for all hospitalisations. Patients with MDR TB who were immunosuppressed spent 70 days in hospital.
Measure of benefits used in the economic analysis
The primary outcome of interest was the number of cases cured.
Direct costs
Future costs were discounted at a rate of 3%. Quantities and costs were reported separately. Direct costs included all costs of curative and preventive TB treatment (based on inpatient and outpatient medical and non-medical resource use). The quantity/cost boundary adopted was that of the health service. The estimation of quantities and costs was based on actual data. Cost data were obtained from outpatient records, staff interviews at the TB clinics and the published literature. The price year was 1992.
Statistical analysis of costs
Not reported.
Indirect Costs
Not included.
